ABI 5366
Alternative Names: ABI-5366Latest Information Update: 30 Sep 2024
At a glance
- Originator Assembly Biosciences
- Class Antivirals; Small molecules
- Mechanism of Action DNA helicase-primase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Herpes simplex virus type 2 infections
Most Recent Events
- 23 Sep 2024 Adverse events and pharmacokinetics data from a phase Ia/Ib trial in Herpes simplex virus type 2 infections released by Assembly Biosciences
- 23 Sep 2024 Assembly Biosciences plans a phase II trial for Herpes simplex virus type 2 infections
- 15 Jul 2024 Pharmacodynamics and pharmacokinetics data from a phase Ia/Ib trial in Herpes simplex virus infections released by Assembly Biosciences